230 related articles for article (PubMed ID: 24847087)
1. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
[TBL] [Abstract][Full Text] [Related]
2. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.
Pallud J; Blonski M; Mandonnet E; Audureau E; Fontaine D; Sanai N; Bauchet L; Peruzzi P; Frénay M; Colin P; Guillevin R; Bernier V; Baron MH; Guyotat J; Duffau H; Taillandier L; Capelle L
Neuro Oncol; 2013 May; 15(5):595-606. PubMed ID: 23393207
[TBL] [Abstract][Full Text] [Related]
3. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
7. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
8. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
11. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
13. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
14. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
15. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A
Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Kim D; Kim S; Kim SH; Chang JH; Yun M
Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
[TBL] [Abstract][Full Text] [Related]
17. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
19. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.
Gozé C; Mansour L; Rigau V; Duffau H
J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999
[TBL] [Abstract][Full Text] [Related]
20. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
